GlassScriptPhysician profile
Ashley Gray Mackey
NPI 1619620614
$5,232.14
in general payments reported to CMS, 2019-2025
38 companies · $1,476 in 2025
The $1,476 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $513 · 2023: $1,748 · 2024: $1,495 · 2025: $1,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,718 · Education: $1.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,718.15 |
| Education | $1.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $610.08 | 2023-2025 | Krystexxa, Tavneos, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $592.48 | 2022-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $425.68 | 2022-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $376.60 | 2023 | Krystexxa |
| Vifor Pharma, INC. | $290.22 | 2022-2024 | Veltassa |
| Novo Nordisk INC | $286.02 | 2022-2025 | Ozempic, Rybelsus |
| Travere Therapeutics, INC. | $237.16 | 2023-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $228.17 | 2022-2024 | Lupkynis |
| Takeda Pharmaceuticals U.S.A., INC. | $213.48 | 2022-2023 | Livtencity |
| Calliditas Therapeutics US INC. | $205.32 | 2024-2025 | Tarpeyo |
| Veloxis Pharmaceuticals, INC. | $167.83 | 2022-2023 | Envarsus |
| Bayer Healthcare Pharmaceuticals INC. | $156.54 | 2024-2025 | |
| Ardelyx, INC. | $143.30 | 2024-2025 | Ibsrela |
| Cormedix INC. | $131.95 | 2024-2025 | Defencath, Defencath |
| Glaxosmithkline, LLC. | $130.92 | 2023-2024 | Jesduvroq |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Mackey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.